As patients with ALPS often experience defects in apoptosis, the impact of leniolisib on these mechanisms as well as on levels of interleukin 10, soluble Fas ligand, lipids, vitamin B12, and phosphorylated AKT/S6 levels warrants further investigation. The gene discussed is FASLG; the disease is autoimmune lymphoproliferative syndrome.